It is well-known that either primary PAH, familial PAH, or secondary pulmonary hypertension are characterized by mutations in the BMPR2 gene and along the TGFβ signaling pathway, which include SMAD4, SMAD9, CAV1, and ENG. This was confirmed in our analysis. This evidence concerns the gene CAV1 and pulmonary arterial hypertension.